Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

BACKGROUND: Cardiotoxicity is the most significant adverse event associated with trastuzumab (T), the main component of HER2-positive breast cancer (BC) treatment. Less is known about the cardiotoxicity of dual HER2 blockade with T plus lapatinib (L), although this regimen is used in the metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Eiger, Daniel, Pondé, Noam F., Agbor-Tarh, Dominique, Moreno-Aspitia, Alvaro, Piccart, Martine, Hilbers, Florentine S., Werner, Olena, Chumsri, Saranya, Dueck, Amylou, Kroep, Judith R., Gomez, Henry, Láng, István, Rodeheffer, Richard J., Ewer, Michael S., Suter, Thomas, de Azambuja, Evandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217956/
https://www.ncbi.nlm.nih.gov/pubmed/32203207
http://dx.doi.org/10.1038/s41416-020-0786-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217956/
https://www.ncbi.nlm.nih.gov/pubmed/32203207
http://dx.doi.org/10.1038/s41416-020-0786-x

Ejemplares similares